[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100526960":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":22,"centralContacts":28,"locations":35,"responsibleParty":49,"collaborators":51,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":66,"eligibilityCriteria":67,"healthyVolunteers":62,"sex":68,"minAge":69,"maxAge":70,"enrollmentInfo":71,"targetDuration":10,"studyType":74,"phases":10,"briefSummary":75,"conditions":76,"keywords":79,"overallStatus":82,"whyStopped":10,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"First Affiliated Hospital Xi'an Jiaotong University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Experimental group",null,"Adequate and regular anticoagulant therapy. Anticoagulation therapy is determined based on the patient's CHADS₂ or CHA₂DS₂-VASc score. Anticoagulant medications include vitamin K antagonists, novel oral anticoagulants (NOACs), and aspirin.",[13],"Other: Observational; No Interventions were given.",{"label":15,"type":10,"description":16,"interventionNames":17},"Control group","Patients who have not received regular or continuous anticoagulation therapy due to poor compliance or other reasons.",[13],[19],{"type":6,"name":20,"description":20,"armGroupLabels":21,"otherNames":10},"Observational; No Interventions were given.",[15,9],[23,26],{"name":24,"affiliation":5,"role":25},"Guoliang Li","PRINCIPAL_INVESTIGATOR",{"name":27,"affiliation":5,"role":25},"Chaofeng Sun",[29,33],{"name":24,"role":30,"phone":31,"phoneExt":10,"email":32},"CONTACT","+8613759982523","liguoliang_med@163.com",{"name":27,"role":30,"phone":10,"phoneExt":10,"email":34},"cfsun1@mail.xjtu.edu.cn",[36],{"facility":37,"status":10,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":10},"First Affiliated Hospital of Xian Jiantong University","Xi'an","Shaanxi","710061","China","CN",{"type":44,"coordinates":45},"Point",[46,47],108.92861,34.25833,{"lat":47,"lon":46},{"type":50,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[52,54,56,58],{"name":53,"class":6},"521 Hospital of NORINCO Group",{"name":55,"class":6},"Shaanxi Provincial People's Hospital",{"name":57,"class":6},"Xiangyang Central Hospital",{"name":59,"class":6},"Henan Provincial People's Hospital","100526960","response-of-intracardiac-thrombus-to-anticoagulants-in-patients-with-non-valvular-atrial-fibrillation-lysis-100526960",false,"NCT06141538","Response of Intracardiac Thrombus to Anticoagulants in Patients With Non-valvular Atrial Fibrillation (LYSIS)","Response of Intracardiac Thrombus to Anticoagulants in Patients With Non-valvular Atrial Fibrillation (LYSIS): an Investigator-initiated, National, Multicenter, Retrospective-prospective, Observational Cohort Study","LYSIS","Inclusion Criteria:\n\n* Age ≥18 years old, age ≤80 years old\n* Patients with atrial fibrillation detected by routine surface 12-lead electrocardiography or Holter\n* Transesophageal echocardiography confirmed the presence of cardiac thrombus, and the patient had not received any anticoagulant therapy\n\nExclusion Criteria:\n\n* Echocardiography confirmed valvular heart disease\n* Contraindications to anticoagulants\n* Patients with the previous history of hemorrhagic stroke\n* Low platelet count or functional platelet defects\n* Congenital or acquired coagulation or bleeding disorders\n* Abnormal liver function (liver enzymes \\>2 times the upper limit)\n* Renal failure (endogenous creatinine clearance \\\u003C30ml\u002Fmin)\n* Surgery was planned within the intended study time or had been operated within 30 days before the study\n* Other comorbidities that can cause bleeding, such as tumors\n* Patients with autoimmune diseases or immunodeficiency, or patients who are currently using immunosuppressants and immunomodulators\n* Patients are currently participating in other clinical studies","ALL","18 Years","80 Years",{"count":72,"type":73},500,"ESTIMATED","OBSERVATIONAL","This study aims to analyze changes in the immune status, metabolic status, and host microbiome community structure in non-valvular atrial fibrillation patients with intracardiac thrombus. Additionally, the study aims to analyze factors that influence the responsiveness and occurrence of adverse events related to anticoagulant therapy.",[77,78],"Atrial Fibrillation","Intracardiac Thrombus",[77,78,80,81],"Anticoagulation Therapy","Major adverse cardiovascular and cerebrovascular events","NOT_YET_RECRUITING","2024-04-02",{"date":85,"type":86},"2024-04-04","ACTUAL",{"date":88,"type":73},"2024-12-31",{"date":90,"type":73},"2030-12-31",{"name":5,"class":6},1]